Profiling of the drug-able kinome in addition with transcriptome analyses suggest that SOX4 alone and in combination with SMARCA4 may modulate unique gene expression programs that contribute to breast-cancer genesis, progression, and response to therapy. This evidence concerns the gene SMARCA4 and breast carcinoma.